Literature DB >> 27761002

Intrarenal renin-angiotensin system activity is augmented after initiation of dialysis.

Naro Ohashi1, Shinsuke Isobe1, Sayaka Ishigaki1, Takahisa Suzuki2, Masafumi Ono3, Tomoyuki Fujikura1, Takayuki Tsuji1, Akihiko Kato3, Seiichiro Ozono2, Hideo Yasuda1.   

Abstract

Circulating renin-angiotensin system (RAS) activation is maintained after renal function has deteriorated. The activation of the intrarenal RAS plays a critical role in the pathophysiology of chronic kidney disease (CKD), independently of the circulating RAS. However, the activation of intrarenal RAS and the chymase-dependent pathway after initiation of dialysis has not been clarified. We recruited 19 CKD patients (10 without dialysis and 9 with dialysis) who underwent a heminephrectomy. Circulating RAS was investigated before nephrectomy. The levels of intrarenal RAS components and chymase-positive cells were investigated using radioimmunoassay or immunoblot analysis on samples collected from the removed kidney. Renal damage was evaluated by the extent of tubulointerstitial fibrosis. No significant differences in circulating RAS between nondialysis and dialysis patients were found. However, intrarenal angiotensin II (AngII) and the extent of tubulointerstitial fibrosis in dialysis patients were significantly increased when compared with nondialysis patients. Prorenin and angiotensin-converting enzyme (ACE) levels were dramatically decreased in accordance with renal dysfunction. On the other hand, chymase-positive cells and AngII type 1 receptor (AT1R) expression was significantly increased in dialysis patients when compared with nondialysis patients. In multiple linear regression analyses, there were significant positive and negative relationships between the extent of interstitial fibrosis and angiotensinogen (β=0.45, P=0.042) and prorenin levels (β=-0.85, P<0.01), respectively. In summary, a decrease in prorenin and ACE expression and an increase in chymase, angiotensinogen and AT1R expression in the kidney may augment the intrarenal RAS activation and be associated with renal damage, even after initiation of dialysis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27761002     DOI: 10.1038/hr.2016.143

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  43 in total

1.  Human prorenin has "gate and handle" regions for its non-proteolytic activation.

Authors:  Fumiaki Suzuki; Makoto Hayakawa; Tsutomu Nakagawa; Uddin Mohammad Nasir; Akio Ebihara; Atsushi Iwasawa; Yuichi Ishida; Yukio Nakamura; Kazuo Murakami
Journal:  J Biol Chem       Date:  2003-04-08       Impact factor: 5.157

Review 2.  Local angiotensin II-generating system in vascular tissues: the roles of chymase.

Authors:  M Miyazaki; S Takai
Journal:  Hypertens Res       Date:  2001-05       Impact factor: 3.872

3.  Angiotensin II receptor blocker partially ameliorated intrarenal hypoxia in chronic kidney disease patients: a pre-/post-study.

Authors:  K Manotham; B Ongvilawan; P Urusopone; S Chetsurakarn; J Tanamai; P Limkuansuwan; K Tungsanga; S Eiam-Ong
Journal:  Intern Med J       Date:  2012-04       Impact factor: 2.048

4.  Pre-transplant bilateral native nephrectomy for medically refractory hypertension.

Authors:  R E Power; J G Calleary; D P Hickey
Journal:  Ir Med J       Date:  2001 Jul-Aug

5.  Enhanced intrarenal receptor-mediated prorenin activation in chronic progressive anti-thymocyte serum nephritis rats on high salt intake.

Authors:  Yanjie Huang; Tatsuo Yamamoto; Taro Misaki; Hiroyuki Suzuki; Akashi Togawa; Naro Ohashi; Hirotaka Fukasawa; Yoshihide Fujigaki; Atsuhiro Ichihara; Akira Nishiyama; Takaaki Senbonmatsu; Naoki Ikegaya; Akira Hishida
Journal:  Am J Physiol Renal Physiol       Date:  2012-04-11

Review 6.  Cardiac angiotensin II formation: the angiotensin-I converting enzyme and human chymase.

Authors:  H Urata; D Ganten
Journal:  Eur Heart J       Date:  1993-11       Impact factor: 29.983

Review 7.  The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.

Authors:  Atsuhisa Sato
Journal:  Hypertens Res       Date:  2015-03-12       Impact factor: 3.872

8.  Role of activated intrarenal reactive oxygen species and renin-angiotensin system in IgA nephropathy model mice.

Authors:  Naro Ohashi; Akemi Katsurada; Kayoko Miyata; Ryousuke Satou; Toshie Saito; Maki Urushihara; Hiroyuki Kobori
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-03-02       Impact factor: 2.557

9.  Intrarenal RAS activity and urinary angiotensinogen excretion in anti-thymocyte serum nephritis rats.

Authors:  Naro Ohashi; Tatsuo Yamamoto; Yanjie Huang; Taro Misaki; Hirotaka Fukasawa; Hiroyuki Suzuki; Akashi Togawa; Sayuri Suzuki; Yoshihide Fujigaki; Tsutomu Nakagawa; Yukio Nakamura; Fumiaki Suzuki; Masatoshi Kitagawa; Akira Hishida
Journal:  Am J Physiol Renal Physiol       Date:  2008-09-10

10.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

View more
  5 in total

1.  Intrarenal renin-angiotensin system activation in end-stage renal disease.

Authors:  Maki Urushihara; Hiroyuki Kobori
Journal:  Hypertens Res       Date:  2017-02-09       Impact factor: 3.872

Review 2.  Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting.

Authors:  Hui Lin; Frank Geurts; Luise Hassler; Daniel Batlle; Katrina M Mirabito Colafella; Kate M Denton; Jia L Zhuo; Xiao C Li; Nirupama Ramkumar; Masahiro Koizumi; Taiji Matsusaka; Akira Nishiyama; Martin J Hoogduijn; Ewout J Hoorn; A H Jan Danser
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

3.  Melatonin ameliorates intrarenal renin-angiotensin system in a 5/6 nephrectomy rat model.

Authors:  Sayaka Ishigaki; Naro Ohashi; Takashi Matsuyama; Shinsuke Isobe; Naoko Tsuji; Takamasa Iwakura; Tomoyuki Fujikura; Takayuki Tsuji; Akihiko Kato; Hiroaki Miyajima; Hideo Yasuda
Journal:  Clin Exp Nephrol       Date:  2017-11-20       Impact factor: 2.801

Review 4.  Possible benefits of exogenous melatonin for individuals on dialysis: a narrative review on potential mechanisms and clinical implications.

Authors:  Seyed Majid Mousavi Movahhed
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-06-07       Impact factor: 3.000

Review 5.  Oncogenic mechanisms in renal insufficiency.

Authors:  Simona Ruxandra Volovat; Constantin Volovat; Ingrith Miron; Mehmet Kanbay; David Goldsmith; Cristian Lungulescu; Silvia Corina Badarau; Adrian Covic
Journal:  Clin Kidney J       Date:  2020-10-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.